Clinical Corner: Invited ReviewUterine fibroids in menopause and perimenopauseUlin, Mara MD1,*; Ali, Mohamed BPharm, MSc1,2,*; Chaudhry, Zunir Tayyeb MD3; Al-Hendy, Ayman MD, PhD1; Yang, Qiwei PhD1Author Information 1Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, IL 2Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt 3St. James School of Medicine, St Vincent, Caribbean. Address correspondence to: Qiwei Yang, PhD, Department of Obstetrics and Gynecology, University of Illinois at Chicago, Chicago, IL 60612. E-mail: email@example.com Received 30 April, 2019 Revised 29 July, 2019 Accepted 29 July, 2019 Funding/support: This work was supported in part by the National Institutes of Health grants: R01 HD094378, R01 ES028615, and U54 MD007602. Financial disclosure/conflicts of interest: AA-H is a consultant for Allergan, Bayer, Repros, and Myovant Sciences, as well as AbbVie. The other authors have nothing to disclose. Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.menopause.org). Online date: November 18, 2019 Menopause: February 2020 - Volume 27 - Issue 2 - p 238-242 doi: 10.1097/GME.0000000000001438 Buy SDC Metrics Abstract Uterine fibroids (UFs) are benign tumors that arise from a single genetically altered mesenchymal stem cell under the influence of gonadal hormones. UFs are the most common benign gynecologic tumors in premenopausal women worldwide. It is estimated that nearly 70% to 80% of women will develop UFs at some point during their lifetime. UFs often present with abnormal uterine bleeding (AUB), pelvic fullness, and may have deleterious effects on fertility. The natural regression of UFs begins in menopause. This is, however, a generality as this pathology may still be present in this age group. Many clinicians are concerned about hormone therapy (HT) because of UFs regrowth; nevertheless, research of this subject remains inconclusive. If UFs are present in perimenopause or menopause, they typically manifest as AUB, which represents up to 70% of all gynecological consultations in perimenopausal and postmenopausal women. As AUB is a broad symptom and may not be specific to UFs, a thorough evaluation is required for correct diagnosis and proper treatment accordingly. Understanding the unique characteristics of the available treatment modalities is crucial in deciding the appropriate treatment approach. Decision on treatment modality should be made based on selection of the least morbidity and lowest risk for each patient. Multiple modalities are available; however, surgery remains the method of choice, with the best cure rates. Various attempts to create an inexpensive, safe, and effective drug for the treatments of UFs are still in the early stages of the clinical trials with some showing great promise. Treatment options include tibolone, aromatase inhibitors, selective estrogen receptor modulators, uterine artery embolization, and selective progesterone receptor modulators. Video Summary:http://links.lww.com/MENO/A493. © 2020 by The North American Menopause Society.